- MEI Pharma Inc MEIP and Infinity Pharmaceuticals Inc INFI have entered into a definitive merger agreement for an all-stock transaction forming a company focusing on three clinical-stage oncology drug candidates.
- Infinity's Eganelisib is planned to be evaluated in combination with Merck & Co Inc MRK Keytruda (pembrolizumab) in patients with head and neck squamous cell carcinoma (HNSCC).
- Related: Infinity Pharma Posts 52% Increase In One-Year Progression-Free Survival Rate In Breast Cancer Patients.
- MEI Pharma's Voruciclib is currently being studied with AbbVie Inc's ABBV Venclexta (venetoclax) for hematologic malignancies.
- MEI Pharma's ME-344 will be evaluated with Roche Holdings AG's RHHBY Avastin (bevacizumab) for relapsed colorectal cancer.
- Related: MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic Alternatives.
- Infinity will become a wholly-owned subsidiary of MEI Pharma.
- MEI Pharma shareholders are expected to own approximately 58.0%, and pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.
- The merger is expected to close in mid-2023.
- Projected ~$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months.
- Price Action: MEIP shares are down 15.30% at $0.25, and INFI shares are down 45.50% at $0.30 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
